SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors weigh an upsized equity offering against high-conviction buyout rumors, with the community closely tracking upcoming phase 3 psoriatic arthritis data as a major de-risking catalyst. Many discuss the stock's potential for a significant rerating or acquisition, noting the strong clinical data in hidradenitis suppurativa and the strategic value of sonelokimab as a best-in-class immunology asset.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck (MRK) is currently the subject of intense buyout speculation, with community discussions centering on the company's urgent need to address an impending patent cliff for its blockbuster drug, Keytruda. Investors are actively debating potential strategic acquisitionsspecifically highlighting Sellas Life Sciences (SLS) and othersas essential moves to secure long-term patent protection and maintain market dominance in oncology.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility and a massive sell-off as traders react to a critical security vulnerability that potentially allowed for the creation of counterfeit coins. While the team has deployed a patch, the community is deeply divided, with some viewing the dip as a high-stakes buying opportunity and others expressing concerns that the privacy-focused nature of the chain makes it impossible to verify if the flaw was exploited.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML remains a central pillar of the global semiconductor industry as investors closely watch how the ongoing AI infrastructure buildout drives demand for its critical extreme ultraviolet (EUV) lithography systems. Community sentiment is currently focused on the company's long-term competitive moat and its indispensable role in the production roadmaps of major chip foundries, leading many to monitor the stock as a key benchmark for the broader semiconductor equipment sector.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is currently a focal point for investors as high short interest and anticipation of a turnaround, spurred by the return of its founder as CEO and significant insider stock purchases, spark intense debate over its potential for a short squeeze. While bulls highlight institutional accumulation and strategic positioning in enterprise agentic AI, bears remain skeptical of the company's historical revenue performance and ongoing cash burn.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as investors weigh its ongoing integration of stablecoin and AI-driven payment infrastructure against potential regulatory headwinds involving credit card interest rate caps. The community remains focused on the stock's long-term compounding potential, actively debating whether recent pullbacks represent a tactical buying opportunity for a resilient digital payments leader or a structural shift in sector valuation.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

The Grayscale Ethereum Mini Trust is trending as investors debate the impact of institutional capital inflows, regulatory clarity, and a potential pivot toward Ethereum-based infrastructure and RWA tokenization. Community discourse is heavily focused on long-term accumulation strategies versus short-term volatility, with many users tracking the correlation between ETH and broader crypto market health.

RoboStrategy is a venture capital investment firm that publicly trades a fund giving investors access to private & public companies leading in robotics and embodied AI.

RoboStrategy Inc

RoboStrategy, Inc.

RoboStrategy, Inc. is gaining significant momentum as investors rotate into robotics and physical AI, fueled by the fund's direct exposure to prominent, high-value pre-IPO companies like Figure AI. The community is actively debating its valuation against private holdings while closely tracking high-volume volatility and potential for long-term thematic growth.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. shares are surging following the company's decision to slash its workforce by 40% in a strategic pivot toward AI-driven automation and enhanced operational efficiency. The community is actively debating whether this move is a necessary fix for long-standing corporate bloat or a desperate attempt to prop up a struggling business model, with many investors weighing the aggressive cost-cutting against the company's competitive position in the fintech landscape.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors digest a volatile period of institutional outflows and shifting regulatory sentiment surrounding Bitcoin's role as a digital asset. Community members are intensely debating whether recent price fluctuations represent a long-term bottom for institutional adoption or a sign of deeper structural instability within the crypto-linked equity space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransMedics Completes PAD Aviation Investment to Expand in Europe

TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.

Where Will TransMedics Group Stock Be in 10 Years?

Where Will TransMedics Group Stock Be in 10 Years...

TMDX Stock Rallies As Analyst Sees 77% Upside  — Here’s Why  

Equity

TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target. 


Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

TransMedics (NASDAQ: TMDX) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market rea...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass., May 21, 2026 ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a...

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference TransMedics to Present at the William Blair 46th Annual Growth Stock Conference PR Newswire ANDOVER, Mass., May 19...

TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group dropped their target price on TransMedics Group from $152.00 to $124.00 and set a 'buy' rating on the stock in a research report on Wednesday...

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Bearish Sentiment

Buying - this is temporary noise

Holding existing position

Selling / Trimming / Shorting

Watching from the sidelines

$TMDX is sliding after Stifel flagged a surge in "dry runs.". TransMedics investors are divided: is this a temporary operational blip or a structural crack in the growth story? Cast your vote below.

$TMDX sliding on &quot;dry run&quot; concerns - are you buying this dip?

Stocktwits

 sliding on "dry run" concerns - are you buying this dip?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.53	--	--	N/A
Q1 '26	$0.60	$0.30	-49.84%	MISSED
Q4 '25	$0.44	$2.62	500.36%	BEAT
Q3 '25	$0.36	$0.66	83.06%	BEAT
Q2 '25	$0.45	$0.92	104.44%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMDXTransmedics Group Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest TMDX News